Bone Sialoprotein as a Marker in Multiple Myeloma
Author Information
Author(s): Woitge H W, Pecherstorfer M, Horn E, Keck A-V, Diel I J, Bayer P, Ludwig H, Ziegler R, Seibel M J
Primary Institution: Department of Medicine I, University of Heidelberg
Hypothesis
Can serum bone sialoprotein (BSP) serve as a clinical guide in patients with plasma cell dyscrasias?
Conclusion
Serum BSP levels are associated with skeletal involvement and tumor cell burden in multiple myeloma.
Supporting Evidence
- Serum BSP levels were higher in multiple myeloma patients compared to healthy controls.
- BSP levels correlated with the bone marrow plasma cell content.
- BSP reflected the response to treatment after chemotherapy.
- Patients with normal baseline BSP levels survived longer than those with elevated levels.
Takeaway
This study found that measuring a substance called bone sialoprotein in the blood can help doctors understand how serious multiple myeloma is and how well treatment is working.
Methodology
Serum BSP concentrations were measured in patients with multiple myeloma, monoclonal gammopathy of undetermined significance, benign vertebral osteoporosis, and healthy adults.
Participant Demographics
62 patients with newly diagnosed multiple myeloma, 46 with MGUS, 71 with benign vertebral osteoporosis, and 139 healthy adults.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website